Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on December 8, 2003

Circulation. 2003
Published online before print December 8, 2003, doi: 10.1161/01.CIR.0000105725.61763.A2
A more recent version of this article appeared on January 6, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
109/1/132    most recent
01.CIR.0000105725.61763.A2v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakashima, H.
Right arrow Articles by Morishita, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakashima, H.
Right arrow Articles by Morishita, R.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Related Collections
Right arrow Gene therapy

Submitted on July 26, 2003
Revised on August 25, 2003
Accepted on August 26, 2003

Inhibition of Experimental Abdominal Aortic Aneurysm in the Rat by Use of Decoy Oligodeoxynucleotides Suppressing Activity of Nuclear Factor {kappa}B and ets Transcription Factors

Hideki Nakashima MD, Motokuni Aoki MD, PhD, Takashi Miyake MD, Tomio Kawasaki MD, PhD, Masahiro Iwai PhD, Nobuo Jo MD, Masako Oishi PhD, Kazusaburo Kataoka PhD, Shigetsugu Ohgi MD, PhD, Toshio Ogihara MD, PhD, Yasufumi Kaneda MD, PhD, and Ryuichi Morishita MD, PhD*

From the Division of Gene Therapy Science (H.N., N.J., Y.K.), the Department of Geriatric Medicine (M.A., T.O.), the Division of Clinical Gene Therapy (T.M., R.M.), the Division of Cardiovascular Surgery (M.I.), and the Department of Pharmacy (H.N., M.O., K.K.), Graduate School of Medicine, Osaka University, Osaka, Japan; Ono Pharmaceutical Company Ltd (M.I.), Osaka, Japan; and the Second Department of Surgery (S.O.), Faculty of Medicine, Tottori University, Yonago, Japan.

* To whom correspondence should be addressed. E-mail: morishit{at}cgt.med.osaka-u.ac.jp.

Background--Two phenomena, inflammation and matrix degradation, contribute to the progression of abdominal aortic aneurysm (AAA). Importantly, the inflammation is regulated by the transcription factor nuclear factor (NF)-{kappa}B, whereas the destruction and degradation of elastin fibers by matrix metalloproteinases (MMP) are regulated by ets. Thus, we developed a novel strategy to treat AAA by simultaneous inhibition of both NF-{kappa}B and ets by using chimeric decoy oligodeoxynucleotides (ODN).

Methods and Results--AAA was induced in rats by transient aortic perfusion with elastase, whereas transfection of decoy ODN was performed by wrapping a delivery sheet containing decoy ODN around the aorta. Gel-mobility shift assay at 7 days after treatment demonstrated that both NF-{kappa}B and ets binding activity were simultaneously inhibited by chimeric decoy ODN. Transfection of chimeric decoy ODN resulted in significant inhibition of the progression of AAA such as aneurysmal dilation at 4 weeks after treatment as compared with control, accompanied by a reduction of MMP expression. Moreover, the destruction of elastin fibers was inhibited in the aorta transfected with chimeric decoy ODN. Importantly, transfection of chimeric decoy ODN demonstrated potent inhibition of aneurysmal dilatation compared with NF-{kappa}B decoy ODN alone, whereas scrambled decoy ODN had no effects. Interestingly, the migration of macrophages was significantly inhibited by chimeric decoy ODN.

Conclusions--We demonstrated that inhibition of the progression of AAA was achieved by a novel strategy with chimeric decoy ODN used against NF-{kappa}B and ets in rat model. NF-{kappa}B and ets are considered to play an important role in the pathogenesis of AAA.


Key words: aneurysm • aorta • inflammation • gene therapy • metalloproteinase




This article has been cited by other articles:


Home page
CirculationHome page
T. Aoki, H. Kataoka, M. Shimamura, H. Nakagami, K. Wakayama, T. Moriwaki, R. Ishibashi, K. Nozaki, R. Morishita, and N. Hashimoto
NF-{kappa}B Is a Key Mediator of Cerebral Aneurysm Formation
Circulation, December 11, 2007; 116(24): 2830 - 2840.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Miyake, M. Aoki, H. Masaki, T. Kawasaki, M. Oishi, K. Kataoka, T. Ogihara, Y. Kaneda, and R. Morishita
Regression of Abdominal Aortic Aneurysms by Simultaneous Inhibition of Nuclear Factor {kappa}B and Ets in a Rabbit Model
Circ. Res., November 26, 2007; 101(11): 1175 - 1184.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
A.-M. Park and Y. J. Suzuki
Effects of intermittent hypoxia on oxidative stress-induced myocardial damage in mice
J Appl Physiol, May 1, 2007; 102(5): 1806 - 1814.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. Shiraya, K. Miwa, M. Aoki, T. Miyake, M. Oishi, K. Kataoka, S. Ohgi, T. Ogihara, Y. Kaneda, and R. Morishita
Hypertension Accelerated Experimental Abdominal Aortic Aneurysm Through Upregulation of Nuclear Factor {kappa}B and Ets
Hypertension, October 1, 2006; 48(4): 628 - 636.
[Abstract] [Full Text] [PDF]